U.S. stocks closed lower Wednesday, October 7, 2026, as investors weighed elevated Treasury yields, the possibility of another Federal Reserve rate increase and uneven signals about consumer demand. The Dow Jones Industrial Average fell 341.41 points, or 0.66%, while the S&P 500 and Nasdaq Composite each slipped 0.22%, retreating from Tuesday’s record closes. Small-cap stocks underperformed, with the Russell 2000 declining 1.31%. The session’s central theme was selectivity: enthusiasm for artificial intelligence and corporate earnings continued to support parts of the market, but higher financing costs and persistent inflation risks challenged the broader rally. A strong Treasury auction helped yields retreat from their intraday highs, while newly released Fed minutes preserved the prospect of another rate hike without establishing its timing.

Stock Market Closing Performance: October 7, 2026

Why Stocks Fell: Rising Yields Challenged the Record Rally

Wednesday’s decline followed a strong Tuesday session, when the S&P 500 recorded its first close above 7,800. The pullback was modest for the large-cap benchmarks but more pronounced for the Dow and Russell 2000, indicating that strength at the top of the market did not translate into broad participation. Bond-market pressure remained a major concern. The 10-year Treasury yield climbed to approximately 5.35%–5.36% during Wednesday’s session, its highest level since 2002, before retreating. The 30-year yield also reached a multidecade high before easing. The distinction matters: stocks faced unusually high yields during the trading day even though the supplied end-of-day snapshot showed the 10-year back at 5.28%. Wednesday therefore reflected both a financing-cost shock and a partial recovery in demand for government bonds, rather than an uninterrupted rise in yields through the close.

Macroeconomic Commentary: Fed Minutes Meet a Changing Economy

Another rate hike remains possible, but timing is unsettled

Minutes from the Federal Reserve’s September meeting showed broad support for the quarter-percentage-point rate increase approved that month. Most participants also believed another increase would likely be appropriate before year-end, while emphasizing that future decisions would depend on incoming information. The next scheduled policy decisions are October 28 and December 9. However, the minutes describe policymakers’ thinking in September, not a fresh assessment incorporating every subsequent economic release. Since that meeting, softer inflation and employment readings have complicated the case for an immediate follow-up hike. August core personal consumption expenditures inflation registered 3.0% year over year, below the expected 3.3% and down from July’s 3.3%. September payroll growth was just 29,000, while unemployment rose to 4.2% from 4.1%. These figures reduced the urgency for additional tightening, although inflation remained above the Fed’s 2% target. Futures markets reflected that distinction, assigning approximately a 17% probability to an October increase and roughly a 70% probability to a December hike. Those probabilities represent market expectations, not a commitment from the central bank.

A strong Treasury auction offered relief, not an all-clear

The Treasury’s $39 billion sale of 10-year notes drew strong demand, helping yields retreat from their highs. Indirect bidders, a category that includes foreign central banks and other investors, purchased 80.3% of the offering, compared with a 10-auction average of 72.4%. Dealers took just 2.5%, substantially below their recent average. The auction weakened the argument that buyers were unwilling to absorb U.S. debt at prevailing prices. Nevertheless, its approximately 5.3% yield was the highest for a 10-year auction since 2000. Strong demand provided near-term relief without eliminating the market’s higher-rate backdrop.

Energy logistics remain an inflation risk

A reported $76 million charter for a supertanker traveling from the U.S. Gulf Coast to China illustrated the scale of disruption in global oil transportation. CNBC reported that a comparable pre-war voyage would normally cost $7 million to $10 million. Assuming a two-million-barrel cargo, the reported charter equates to $38 per barrel in shipping costs alone. The report linked the increase to tanker shortages and a shuttle system used to move oil through the Strait of Hormuz while limiting exposure to attacks. The macroeconomic implication is that a modest decline in a quoted crude contract does not necessarily signal relief across the energy supply chain: transportation constraints can remain severe even when benchmark prices fluctuate.

Company News: AI Financing, Retail Earnings and Streaming Sports

SpaceX (SPCX), Nvidia (NVDA) and Apollo Global Management (APO)

SpaceX (SPCX) was in preliminary discussions with Apollo Global Management (APO) and banks over financing a potential $40 billion purchase of Nvidia (NVDA) graphics processing units. CNBC reported that the arrangement would primarily involve investment-grade debt and could use GPUs as collateral; lenders and final terms had not been settled. The story connects the AI investment boom directly to credit markets. Widening AI-related credit spreads and greater investor demands for yield, underscoring that continued infrastructure spending does not necessarily mean inexpensive financing. SpaceX (SPCX) closed down 2.51% at $167.60.

Levi Strauss (LEVI): Higher profit guidance, softer sales expectations

Levi Strauss (LEVI) raised its full-year adjusted earnings outlook to $1.54–$1.56 per share from $1.46–$1.52, helped by tariff refunds. At the same time, it narrowed expected annual revenue growth to 7%, the bottom of its previous range. Shares rose approximately 5% in extended trading, separate from the regular-session index closes above. Quarterly revenue increased roughly 4% to $1.61 billion, but U.S. revenue declined 1% and direct-to-consumer comparable sales were approximately flat. The results illustrate why investors need to distinguish profit improvements supported by refunds from stronger underlying customer demand..

Constellation Brands (STZ): Shipment Growth Outpaced Consumer Demand

Constellation Brands (STZ) reported adjusted quarterly earnings of $3.74 per share on revenue of $2.63 billion, exceeding analyst expectations. Beer revenue rose approximately 5%, and shipments increased 5.5%, but beer depletions, which measure sales from distributors to retailers and other customers, declined slightly. That gap is important: inventory replenishment can lift shipments without demonstrating an equivalent improvement in consumer purchases. The company maintained its full-year adjusted earnings forecast of $11.20–$11.90 per share. The closing quote showed Constellation Brands (STZ) finishing at $118.40, up 2.36%.

Disney (DIS): Super Bowl Streaming Expands Live-Sports Reach

Walt Disney (DIS) announced that Disney+ will stream the 2027 Super Bowl for U.S. subscribers, alongside two Monday Night Football games leading up to the championship. ESPN will produce the Super Bowl, which will also air on ESPN and ABC. The announcement extends the company’s push to incorporate live sports into its streaming offering.

Jaguar: A Premium Electric-Vehicle Repositioning

Jaguar unveiled its all-electric Type 01, with a confirmed North American starting price of $130,000, a stated range of up to 450 miles and acceleration from zero to 62 mph in 3.2 seconds. The launch marks a major repositioning for the automotive brand following its controversial rebranding campaign. No separate Jaguar stock ticker is assigned here because the story concerns the brand rather than an independently listed company.

What Many Are Watching Next

• Treasury demand: Thursday’s scheduled $22 billion auction of 30-year bonds will provide another test of appetite for long-duration government debt following Wednesday’s strong 10-year sale.
• The inflation-employment balance: Upcoming economic releases will help determine whether the softer readings since September represent a sustained change or temporary relief.
• AI financing conditions: The proposed SpaceX (SPCX) financing highlights the growing importance of borrowing costs, collateral assumptions and investor appetite alongside demand for Nvidia (NVDA) chips.
• Underlying consumer spending: Levi Strauss (LEVI) and Constellation Brands (STZ) offered reasons to examine comparable sales and distributor sell-through, rather than simply headline earnings beats.

Wednesday’s market offered a clear tension: large-cap indexes remained near record territory, but the economic and financial conditions supporting those valuations were less comfortable. Treasury demand improved during the session, yet elevated yields, unresolved inflation risks and uneven consumer indicators kept investors cautious.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.64, +3.02%.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $2.01) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $11.63, +.43%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

HPP announced (Oct. 5) that its operating partnership, Hudson Pacific Properties, L.P. (the “Company”), has commenced an offer to purchase for cash (the “Tender Offer”) up to a combined aggregate principal amount of $200,000,000 (the “Aggregate Maximum Tender Offer Amount”) of the Company’s outstanding 3.950% Senior Notes due 2027 (the “2027 Notes”) and 5.950% Senior Notes due 2028 (the “2028 Notes” and together with the 2027 Notes, the “Notes” and each a “Series” of Notes) as shown in the linked story, subject to the Allocation Procedures, including the Proration Factor (each as defined below). The Company is offering to purchase $100,000,000 aggregate principal amount of each Series of Notes (the “Target Allocation”).

HPP turned in a quarter ( Aug. 5) that suggests the office malaise is not over, but it may finally be meeting resistance. Revenue came in above Wall Street’s expectations, occupancy moved higher for a fourth straight quarter, and management raised full-year guidance, a combination that does not make for a triumphant victory lap, but it does make for a more credible turnaround narrative. Learn more.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.78, +.52%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the ongoing RESOLVE study. For a chronic disease in which swallowing can become a calculated exercise rather than an automatic human function, durability is more than a tidy line on a clinical slide. It is central to the value proposition. The latest data suggest Eupraxia’s localized, extended-release approach may be building toward a differentiated position in a market already led by a formidable incumbent: Sanofi S.A. (NASDAQ: SNY) and its biologic franchise, Dupixent. The clinical data remain early, open-label, and small in patient count, biotech investors should keep both feet on the ground, even when the data seem to float, but the one-year observations give EPRX a meaningful argument for continued investor attention ahead of interim randomized Phase 2b results expected in December 2026.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.66), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026 (8:30am PT / 11:30 am ET). You may watch the event video below now if you missed it below now.

MODD announced (Aug. 3) plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company’s capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.

MODD recently (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $2.95) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $2.64, +3.13%), a leading China-based beauty group, delivered the sort of quarter that can make a turnaround investor sit up straighter: reported revenue grew, its strategically important skincare operation accelerated sharply, and the company is increasingly built around clinical and premium brands rather than a pure color-cosmetics play. The results are not yet a victory lap, losses widened and third-quarter guidance is cautious, but YSG’s transformation is beginning to look less like a cosmetic touch-up and more like a genuine renovation.

YSG announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $27.69) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

DOCS announced (Sept. 22) that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform. As part of the launch, Doximity is publishing a new open-source benchmark for measuring clinical-grade AI. Called Bedside Bench, the benchmark has been built to test AI’s ability to be a trusted partner to doctors where it matters most: at the bedside.

Doximity, Inc. (NYSE: DOCS) announced (Aug. 6) results of its fiscal 2027 first quarter ended June 30, 2026. Jeff Tangney, co-founder and CEO of Doximity, “We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

• Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.
• Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.
• Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.
• Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.
• Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

• Revenue between $170 million and $171 million.
• Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

• Revenue between $671 million and $681 million.
• Adjusted EBITDA between $309 million and $329 million.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (NYSE: SOC, $3.67, +2.80%). JPMorgan Chase (NYSE: JPM) initiated coverage of Sable Offshore (NYSE: SOC) with an Overweight rating and a $10 price target October 2. That target implies an approximately 178% gain from today’s prices that are in the $3.59 range. It is an attention-getting valuation gap, even by the standards of an industry accustomed to looking beneath the surface. The more substantive opportunity, however, lies offshore California. Sable is already generating revenue from its Santa Ynez Unit, while preparing to restart Platform Hondo and expand the infrastructure needed to move more oil to market. The bullish thesis is therefore more advanced than a bet on dormant assets: it is a wager for many that an operating business can overcome its remaining bottlenecks and convert additional barrels into stronger cash generation.

Nvidia (NVDA, $237.47, –.74%%)

NVIDIA Corp. (NASDAQ: NVDA). AM Intelligence (“AMI”), the AI infrastructure platform set up by Promoters of Greenko, announced (Oct. 5) two further firm and binding orders for 20,000 NVIDIA Rubin GPUs, to be deployed as NVIDIA Vera Rubin NVL72 rack-scale systems. Building on its first AI factory in Hyderabad, the expansion is designed to give cloud providers, enterprises and AI developers access to large-scale computing capacity closer to where they build and deploy AI.

NVDA recently has seemingly has given many a two-part bullish signal: a record-sized $150 billion increase to its share-repurchase authorization and a new AI-agent safety platform aimed at making autonomous software more secure for enterprise deployment. The combination suggests a company using extraordinary financial strength not merely to reward shareholders, but to expand its influence from AI computing into the governance, security and operating layer of the AI economy. The timing is notable. Markets are beginning the week with a cautiously constructive tone, even as investors brace for jobs, inflation and manufacturing data that could reset the outlook for interest rates. In that environment, NVIDIA is making a familiar but potent argument: its AI franchise is generating enough cash to finance innovation, deepen its ecosystem and return meaningful capital to shareholders, all at once. That is not an everyday corporate trick. It is closer to juggling bowling balls while also building the bowling alley.

The Sources

1. CNBC: Stock Market Today, Live Updates
   https://www.cnbc.com/2026/10/06/stock-market-today-live-updates.html
2. Yahoo Finance: Stock Market Today, Wednesday, October 7
   https://finance.yahoo.com/markets/live/stock-market-today-wednesday-october-7-dow-sp-500-nasdaq-080241833.html
3. CNBC: Fed Officials See Another Hike Coming, but No Sign as to When, Minutes Show
   https://www.cnbc.com/2026/10/07/fed-officials-see-another-hike-coming-but-no-sign-as-to-when-minutes-show.html
4. Yahoo Finance: The Fed Was Unanimous About Raising Rates in September. Economic Signals Have Since Changed.
   https://finance.yahoo.com/economy/policy/article/the-fed-was-unanimous-about-raising-rates-in-september-economic-signals-have-since-changed-184839972.html
5. CNBC: Levi Strauss Q3 2026 Earnings
   https://www.cnbc.com/2026/10/07/levi-strauss-levi-q3-2026-earnings.html
6. CNBC: Supertanker Chartered From the U.S. Gulf Coast to China for $76 Million
   https://www.cnbc.com/2026/10/07/supertanker-from-us-to-china-chartered-for-76-million-source.html
7. CNBC: Treasury Yields, Bond Auction and FOMC Minutes
   https://www.cnbc.com/2026/10/07/treasury-yields-auction-fomc-minutes.html
8. CNBC: Apollo and Banks in Talks to Finance SpaceX’s $40 Billion Nvidia GPU Purchase
   https://www.cnbc.com/2026/10/07/spacex-nvidia-chips-apollo-financing.html
9. CNBC: Jaguar Unveils $130,000 Electric Vehicle Following Brand Reboot
   https://www.cnbc.com/2026/10/07/jaguar-electric-vehicle-autos-type-01.html
10. CNBC: Constellation Brands Earnings and Beer Demand
    https://www.cnbc.com/2026/10/07/constellation-brands-earnings-beer-demand.html
11. CNBC: Disney+ to Stream the 2027 Super Bowl
    https://www.cnbc.com/2026/10/07/disney-stream-super-bowl-2027.html